Efficacy and safety of everolimus in treatment of advanced angiosarcoma

Objective：To investigate the efficacy and safety of mTOR inhibitor everolimus in the treatment of advanced angiosarcoma. Methods：Clinical data of 5 patients with advanced angiosarcoma initially treated with everolimus from November 2013 to September 2018 were collected to observe the efficacy and adverse reactions. Results：The symptoms of 4 patients with advanced angiosarcoma were relieved and the lesions narrowed within a few days after the treatment of everolimus. One patient with advanced angiosarcoma who was resistant to apatinib continued to progress. The main adverse effects of everolimus were oral ulcers, of which 2 cases were grade 2 and 3 cases were grade 1. Conclusions：Everolimus is effective in the treatment of advanced angiosarcoma with rapid onset of action and controllable adverse effects.